Cardiff Oncology IncNASDAQ:CRDF
- LAST PRICE4.3988
- TODAY'S CHANGE (%)0.3288 (8.0786%)
- Bid / Lots4.3600/ 2
- Ask / Lots4.3900/ 3
- Open / Previous Close4.1400 / 4.0700
- Day Range
- 52 Week Range
- Volume110,275
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRDF |
|---|---|---|
| 09:32 ET | 10356 | 4.26 |
| 09:34 ET | 7105 | 4.28 |
| 09:36 ET | 1646 | 4.34 |
| 09:38 ET | 5794 | 4.3501 |
| 09:39 ET | 2196 | 4.41 |
| 09:41 ET | 11552 | 4.399 |
| 09:43 ET | 2377 | 4.3816 |
| 09:45 ET | 4999 | 4.38 |
| 09:48 ET | 11799 | 4.3352 |
| 09:50 ET | 2881 | 4.3199 |
| 09:52 ET | 3200 | 4.3 |
| 09:54 ET | 665 | 4.32 |
| 09:56 ET | 12382 | 4.3456 |
| 09:57 ET | 1650 | 4.36 |
| 09:59 ET | 6697 | 4.39 |
| 10:01 ET | 3620 | 4.39 |
| 10:03 ET | 600 | 4.3988 |
Apr 25, 2024
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update, from 4:05PM ET on Thursday Apr 25, 2024 by Dow Jones
4:05PM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 8, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cardiff Oncology Inc | 181.8M | -4.7x | --- |
Omeros Corp | 182.5M | -1.2x | --- |
Elevation Oncology Inc | 176.1M | -2.3x | --- |
Candel Therapeutics Inc | 187.5M | -4.9x | --- |
Outlook Therapeutics Inc | 188.0M | -2.2x | --- |
Acumen Pharmaceuticals Inc | 190.5M | -3.0x | --- |
Company Information
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has five ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, one trial (CRDF-001) in second-line treatment in patients with mPDAC, and three investigator-initiated trials in first line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.
Contact Information
- Headquarters
- 11055 Flintkote AveSAN DIEGO, CA, United States 92121-1220
- Phone
- 858-952-7570
- Fax
- 858-217-4768
Executives
- Independent Chairman of the Board
- Rodney Markin
- Chief Executive Officer, Director
- Mark Erlander
- Chief Financial Officer
- James Levine
- Chief Operating Officer
- Vicki Kelemen
- Chief Scientific Officer
- Tod Smeal
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $181.8M |
|---|---|
Revenue (TTM) | $488.0K |
Shares Outstanding | 44.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.02 |
EPS | $-0.93 |
Book Value | $1.56 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 372.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -9,305.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
